Irazú Oncology is developing cancer immunotherapies using an Outer Membrane Vesicle (OMV) platform that employs non-replicating, self-adjuvanted, bacteria-derived engineered nanoparticles to display and deliver tumor antigens for antigen presentation. The platform is designed to deliver multiple tumor targets in a single therapy and to generate durable anti-tumor responses. The company is located in the University of Maryland BioPark in Baltimore, Md., and is led by CEO Jeff Strovel. Irazú has participated in TEDCO programs, receiving a Maryland Innovation Initiative Company Formation Award in 2023 and prior Seed Funds support in 2025, and has engaged with TEDCO’s FLLIP Pilot Program and Loaned Executive mentorship. The company states the recent funding will help advance its program toward clinical development. No revenues, user counts, or other operating metrics were disclosed in the announcement.

Total raised

$0M

Funding rounds

2

Latest round

Seed

Latest activity

Jul 2026